Development and Characterization of High-Affinity Anti-Topotecan IgG and Fab Fragments

Handbook of Pharmaceutical Biotechnology

Volumn , Issue , 2006, Pages 835-850

  Chen, Jin ^a   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Anti topotecan IgG (ATI); High affinity anti topotecan IgG and FAB fragments; Hybridomas secreting anti TPT antibodies

Indexed keywords

EID: 84869492008     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470117118.ch06e     Document Type: Chapter

References (19)

1. Balthasar J, Fung H L (1994). Utilization of antidrug antibody fragments for the optimization of intraperitoneal drug therapy: studies using digoxin as a model drug. J. Pharmacol. Experim. Therapeu. 268:734-739.
2. Balthasar J P, Fung H L (1996). Inverse targeting of peritoneal tumors: Selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. J. Pharm. Sci. 85:1035-1043.
3. Balthasar J P, Fung H L (1995). High-affi nity rabbit antibodies directed against methotrexate:production, purifi cation, characterization, and pharmacokinetics in the rat. J. Pharm. Sci. 84:2-6.
4. Lobo E D, Soda D M, Balthasar J P (2003). Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice. J. Pharm. Sci. 92:1665-1676.
5. Lobo E D, Balthasar J P (2005). Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. J. Pharm. Sci. 94:1957-1964.
6. Markman M (1997). Topotecan: An important new drug in the management of ovarian cancer. Semin. Oncol. 24(1 Suppl 5):S5-1.
7. Herben V M, ten Bokkel Huinink W W, Beijnen J H (1996). Clinical pharmacokinetics of topotecan. Clin. Pharmacokinet. 31:85-102.
8. Hsiang Y H, Liu L F (1988). Identifi cation of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1722-1726.
9. Hsiang Y H et al. (1985). Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:14873-14878.
10. Chen J, Balthasar J P (2005). High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 816:183-192.
11. Harlow E, Lane D (1988). Antibodies, A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, M.I., p. 276.
12. Hansen R J, Balthasar J P (1999). An ELISA for quantifi cation of murine IgG in rat plasma: An application to the pharmacokinetic characterization of AP-3, a murine anti-glycoprotein IIIa monoclonal antibody, in the rat. J. Pharmaceu. Biomed. Anal. 21:1011-1016.
13. West G W, Weichselbaum R, Little J B (1980). Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res. 40:3665-3668.
14. Plaxe S C et al. (1998). Phase I and pharmacokinetic study of intraperitoneal topotecan. Invest. New Drugs. 16:147-153.
15. Bazin-Redureau M et al. (1998). Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab′)2. Toxicol. Appl. Pharmacol. 150:295-300.
16. Pentel P R et al. (1988). Pharmacokinetics and toxicity of high doeses of antibody Fab fragments in rats. Drug Metabol. Dispos. 16:141-145.
17. Arend W P, Silverblatt F J (1975). Serum disappearance and catabolism of homologous immunoglobulin fragments in rats. Clin. Exp. Immunol. 22:502-513.
18. Tayab Z R, Balthasar J P (2004). Development and validation of enzyme-linked immunosorbent assays for quantifi cation of anti-methotrexate IgG and Fab in mouse and rat plasma. J. Immunoassay Immunochem. 25:335-344.
19. McClurkan M B et al. (1993). Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats. J. Pharmacol. Experim. Therapeu. 266:1439-1445.